Serum Cystatin C in Patients with Acute Leukemia and its Prognostic Importance

@inproceedings{Seval2017SerumCC,
  title={Serum Cystatin C in Patients with Acute Leukemia and its Prognostic Importance},
  author={Guldane Cengiz Seval and Tuba Çandar and Meltem Ayli and Çağlar Çoşarderelioğlu and Selda Demirtas and Gulsum Ozet and Simten Dagdas and Murat Albayrak and Harika Okutan},
  year={2017}
}
Objective: Serum cystatin C may be over-expressed in some tumour cells and its high serum levels are associated with the poor out come of disease. The aim of this study was to evaluate the serum levels of cystatin-C in acute leukemia patients, explore possible correlations with prognosis. Patients and Methods: Serum samples of patients with newly diagnosis of acute leukemia have been collected at the time of diagnosis from February 2012 until January 2013. Güldane CENGİZ SEVAL1, Tuba CANDAR2… Expand

References

SHOWING 1-10 OF 18 REFERENCES
The Predictive Value of Cystatin C in Monitoring of B Non-Hodgkin Lymphomas: Relation to Biochemical and Clinical Parameters
TLDR
The results indicate that cystatin C should be taken into consideration in disease monitoring, and it is expected that the disease-free and overall survival analysis will give the definitive answer about the reliability of cyStatin C as an indicator of course of aggressive lymphomas. Expand
Prognostic value of cystatin C in patients with nasopharyngeal carcinoma: a retrospective study of 1063 patients
TLDR
A high cystatin C level is an independent indicator of poor prognosis for nasopharyngeal carcinoma patients and is identified as a significant and independent negative predictor of overall survival and loco-regional recurrence-free survival. Expand
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
TLDR
Serum cystatin-C is not only a sensitive marker of renal impairment but also reflects tumor burden and is of prognostic value in multiple myeloma. Expand
Utility of four tumor markers, alone and in combination, for detection of hepatocellular carcinoma: AFP, AFP-L3, DCP, and Cystatin
TLDR
As a single marker, AFP had the highest sensitivity for detecting HCC, followed by DCP, cystatin, and AFP-L3% (Table), and the combination of AFP, DCP and Cystatin C identified 70% of HCC cases with tumor size of 3 cm. Expand
Prognostic significance of serum cystatin C in multiple myeloma
TLDR
Investigating pretreatment serum cystatin C levels in 68 newly diagnosed patients homogeneously treated with high-dose melphalan followed by autologous stem cell transplantation further refined the prognostic information (EFS and OS) provided by either one of the factors. Expand
Serum cystatin C in patients with myeloma.
TLDR
The results suggest that disease burden does not correlate to the circulating level of cystatin C in patients with myeloma. Expand
Serum levels of cystatin C in patients with malignancy
TLDR
The results of this study suggest that the serum levels of cystatin C are not always a reliable marker of the GFR in patients with a malignancy, probably in relation to its nature as a cysteine protease inhibitor. Expand
Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function.
TLDR
Serum cystatin C seems to be a better parameter of GFR than serum creatinine in adults with various types of kidney disease with normal to moderately impaired kidney function. Expand
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
TLDR
The results reveal a correlation between high levels of extracellular cysteine proteinase inhibitors and short survival in patients with colorectal cancer, and the data thus support previous studies suggesting a contributing role of protease inhibitors in the progression of cancer. Expand
Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia.
TLDR
The preliminary data expose that cystatin C is not a reliable GFR marker in patients during leukemia or for monitoring nephrotoxic drugs used in BMT, but can not reach definitive conclusion due to no gold standard for comparing the diagnostic accuracy of cyStatin C. Expand
...
1
2
...